Altimmune ALT
NASDAQ ALT
$2.73 -0.03 (-1.09%)
At close: Oct 2, 2026 · 4:00 PM EDT

Altimmune (ALT) Gains from Sales and Divestitures (2012 - 2017)

Updated

Altimmune (ALT) posted Gains from Sales and Divestitures of $3,806 for FY2018, compared with -$9,182 in FY2017.

Analysis

Altimmune (ALT) Gains from Sales and Divestitures (2012 - 2017) Analysis & Trends

Since FY2011, Altimmune has reported Gains from Sales and Divestitures for 8 years.

  • Annual Gains from Sales and Divestitures shows a five-year compound annual growth rate of 1.7% (FY2013 to FY2018).
  • The FY2018 figure stands as the highest annual Gains from Sales and Divestitures since FY2015.
  • Business Quant data shows ALT's Gains from Sales and Divestitures at -$9,182 in FY2017, -$577.00 in FY2016, $7,600 in FY2015 (+40.9%) and $5,394 in FY2014 (+54.1%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Altimmune 530.91 Mn 530.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 -5,437.00
Sep 30, 2017 -222.00
Dec 31, 2016 -1,264.00
Jun 30, 2016 687.00
Mar 31, 2015 7,600.00
Dec 31, 2014 1.00
Mar 31, 2014 5,393.00
Mar 31, 2012 66,626.00
API Access

Altimmune Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ALT&period=max&api_key=YOUR_API_KEY